1	Multicenter international assessment of a SARS-CoV-2 RT-LAMP test for
2	point of care clinical application
3	Suying Lu ¹⁻³ , David Duplat ⁴ , Paula Benitez-Bolivar ⁴ , Cielo León ⁴ , Stephany D Villota ⁵ , Eliana Veloz-
4	Villavicencio ⁵ , Valentina Arévalo ⁵ , Katariina Jaenes ⁶ , Yuxiu Guo ⁷ , Seray Cicek ⁷ , Lucas Robinson ⁸ ,
5	Philippos Peidis ¹⁻³ , Joel D Pearson ¹⁻³ , Jim Woodgett ^{1,9} , Tony Mazzulli ^{2,10} , Patricio Ponce ⁵ , Silvia
6	Restrepo ¹¹ , John M González ¹² , Adriana Bernal ¹³ , Marcela Guevara-Suarez ¹⁴ , Keith Pardee ^{6,7,15} ,
7	Varsovia E Cevallos ⁵ , Camila González ⁴ , Rod Bremner ^{1-3*}
8	
9	¹ Lunenfeld Tanenbaum Research Institute, Mt Sinai Hospital, Sinai Health System, Toronto, M5G, 1X5,
10	ON, Canada
11	² Department of Laboratory Medicine and Pathobiology,
12	³ Department of Ophthalmology and Vision Science, University of Toronto, Toronto, M5T 3A9, ON,
13	Canada
14	⁴ Centro de Investigaciones en Microbiología y Parasitología Tropical (CIMPAT), Department of
15	Biological Sciences, Universidad de los Andes, Bogotá, Colombia
16	⁵ Centro de Investigación en Enfermedades Infecciosas y Vectoriales (CIREV), Instituto Nacional de
17	Investigación en Salud Pública, Quito, Ecuador.
18	⁶ Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada
19	⁷ LSK Technologies Inc., 151 Charles St W, Kitchener, ON N2G 1H6, Canada
20	⁸ Velocity, University of Waterloo, Kitchener, ON, N2G 1H6, Canada
21	⁹ Department of Medical Biophysics, University of Toronto, Toronto, Canada
22	¹⁰ Department of Microbiology, Sinai Health System/University Health Network, Toronto, Canada
23	¹¹ Department of Food and Chemical Engineering, Universidad de los Andes, Bogotá, Colombia
24	¹² Grupo de Ciencias Básicas Médicas, School of Medicine, Universidad de los Andes, Bogotá, Colombia

- ¹³ Laboratory of Molecular Interactions of Agricultural Microbes (LIMMA), Department of Biological
- 26 Sciences, Universidad de Los Andes, Bogotá, Colombia
- ¹⁴ Applied genomics research group, Vicerrectoría de Investigación y Creación, Universidad de los Andes,
- 28 Bogotá, Colombia
- ¹⁵ Department of Mechanical and Industrial Engineering, University of Toronto, Toronto, M5S 3G8, ON,
- 30 Canada
- 31
- 32 *Corresponding Author
- 33 Email: <u>bremner@lunenfeld.ca</u>

34 Abstract

Continued waves, new variants, and limited vaccine deployment mean that SARS-CoV-2 tests 35 remain vital to constrain the COVID-19 pandemic. Affordable, point-of-care (PoC) tests allow 36 rapid screening in non-medical settings. Reverse-transcription loop-mediated isothermal 37 38 amplification (RT-LAMP) is an appealing approach. A crucial step is to optimize testing in low/medium resource settings. Here, we optimized RT-LAMP for SARS-CoV-2 and human β -39 actin, and tested clinical samples in multiple countries. "TTTT" linker primers did not improve 40 41 performance, and while guanidine hydrochloride, betaine and/or Igepal-CA-630 enhanced 42 detection of synthetic RNA, only the latter two improved direct assays on nasopharygeal 43 samples. With extracted clinical RNA, a 20 min RT-LAMP assay was essentially as sensitive as 44 RT-PCR. With raw Canadian nasopharygeal samples, sensitivity was 100% (95% CI: 67.6% -45 100%) for those with RT-qPCR Ct values ≤ 25 , and 80% (95% CI: 58.4% - 91.9%) for those 46 with $25 < Ct \le 27.2$. Highly infectious, high titer cases were also detected in Colombian and 47 Ecuadorian labs. We further demonstrate the utility of replacing thermocyclers with a portable PoC device (FluoroPLUM). These combined PoC molecular and hardware tools may help to 48 49 limit community transmission of SARS-CoV-2.

50

51 Introduction

With continuing waves of coronavirus disease 2019 (COVID-19) around the world, there has been sustained focus on testing to mitigate and suppress spread of the disease [1]. Limited vaccination and the emergence of new variants [2], most recently Omicron [3], exacerbate

55 recurrent viral surges. Viral shedding in COVID-19 patients peaks on or before symptom onset, 56 and contact tracing and quarantine should be done at a crucial temporal window 2 to 3 days 57 before demonstration of symptoms [4,5], although the exact timing to obtain reliable results is 58 debated [6,7]. Although current gold-standard quantitative real-time polymerase chain reaction (qPCR) assays have sensitive analytical limits of detection (LoD), they are generally performed 59 in sophisticated detection centers with high cost and long turnaround times [8]. Computer 60 modelling studies based on the pattern of viral load kinetics show that effective community 61 control of transmission depends more on testing frequency and shorter turnaround times, than 62 63 analytical LoD [8]. Further, reducing the barriers to testing may also provide significant benefit in settings where point-of-need applications are time sensitive and infrastructure is limited (e.g. 64 school testing and travel). Viral load correlates negatively with cycle threshold (Ct) values and 65 66 positively with infectivity[9]. A few reports suggested that COVID-19 patients with Ct values \leq 25 are more likely to be infectious while patients with Ct values above 33-34 are not contagious 67 [10–12]. Modelling further shows that routine testing substantially reduces risk of COVID-19 68 69 outbreaks in high-risk healthcare environments, and may need to be as frequent as twice weekly [13]. Effective COVID-19 containment demands point-of-care (PoC) tests with short turnaround 70 time, low cost and high accessibility [14]. Indeed, many rapid PoC antigen and molecular-based 71 72 tests for diagnosis of SARS-CoV-2 infection have been developed with a wide range of detection sensitivity and overall high specificity [15]. Some of these tests are approved by regulatory 73 agencies and commercially available [15]. However, the high cost of the rapid antigen tests and 74 the requirement of specialized automated instruments for the molecular-based tests [15] limits 75 accessibility to broad communities. 76

77 Reverse transcription loop-mediated isothermal amplification (RT-LAMP) can be 78 performed in a low-resource setting by merely heating the samples and reagents in a single 79 reaction tube at one constant temperature, and diagnosis is available within 30 minutes [16]. RT-80 LAMP has clear advantages over RT-PCR as a PoC test, and it has been applied to diagnose several viral diseases, such as Severe Acute Respiratory Syndrome (SARS) and Middle East 81 Respiratory Syndrome (MERS), among others [16]. The scientific community has applied RT-82 LAMP to detect SARS-CoV-2 in different kinds of samples, using different primers and 83 experimental readouts. In most of those studies, viral detection required purified RNA or sample 84 85 treatment, and generated variable detection efficiencies [16]. Among seven isothermal tests with Emergency Use Approval (EUA), the LoDs vary up to 50-fold, and are much less sensitive than 86 those of RT-PCR [17]. Recent studies have utilized RT-LAMP on direct patient samples without 87 any RNA purification [18-22], proving feasibility of this approach. However, these studies did 88 not examine assay robustness in different settings, particularly in low resource countries where 89 reagent availability can be a major roadblock. Here, we set out to develop an optimized RT-90 91 LAMP assay and assess feasibility and robustness in different low resource countries.

92 Using a commercially available RT-LAMP kit, we performed systematic primer optimization, and further improved sensitivity with primer multiplexing, and various additives. 93 Using purified RNA as the template, the optimized RT-LAMP assay has similar sensitivity and 94 95 specificity to commercial RT-PCR kits used widely in the clinic. Direct RT-LAMP with raw clinical samples was less efficient, but detected high titer samples from patients predicted to be 96 infectious with high specificity and sensitivity. At a stringent cutoff of 100% specificity (no 97 98 false positives) as FDA recommended [23], labs using the RT-LAMP assay in Canada, Colombia and Ecuador displayed a range of sensitivities, but each could detect highly infectious disease. 99

Finally, using a PoC instrument that enables de-centralized deployment of the RT-LAMP assay, we describe the application of this test on raw unpurified samples. This direct RT-LAMP strategy reduces the barrier to establishing testing capacity by overcoming the need for laboratory infrastructure for RNA extraction or specialized thermocycling and optical monitoring equipment. This detection method has potential as a PoC test to screen individuals with high viral loads and mitigate viral transmission.

106

107 Materials and Methods

108 Oligos

All oligos (Table 1) were ordered from IDT and dissolved with DNase/RNase-free water
at 100µM concentration. The purification method for F3, B3, LF and LB was standard desalting,
and the purification method for FIP and BIP was HPLC. Oligos for each primer set were
combined to make a 10X mix based on required concentrations.

113 Table 1. Primer sets that were optimized for RT-LAMP

Primer name	Primer sequence	Sequence targeted	References	Phase
ORF1a-C-F3	CTGCACCTCATGGTCATGTT	498-517 in GeneBank: MT007544.1	Zhang Y et al.[24]	1ª
ORF1a-C-B3	GATCAGTGCCAAGCTCGTC	704-722 in GeneBank: MT007544.1		
ORF1a-C-LF	ACCACTACGACCGTACTGAAT	ORF1a of SARS-CoV-2		
ORF1a-C-LB	TTCGTAAGAACGGTAATAAAGGAGC			
ORF1a-C-FIP	GAGGGACAAGGACACCAAGTGTGGTAGCAGAACTCGAAGGC			
ORF1a-C-BIP	CCAGTGGCTTACCGCAAGGTTTTAGATCGGCGCCGTAAC			
ORF1a-C-TFIP	GAGGGACAAGGACACCAAGTG <u>TTTT</u> TGGTAGCAGAACTCGAAGGC			
ORF1a-C-TBIP	CCAGTGGCTTACCGCAAGGTT <u>TTT</u> TTAGATCGGCGCCGTAAC			
As1_F3	CGGTGGACAAATTGTCAC	2245-2262 in GeneBank: MT007544.1	Rabe BA <i>et al</i> .[25]	1ª
As1_B3	CTTCTCTGGATTTAACACACTT	2420-2441 in GeneBank: MT007544.1		

As1_LF	TTACAAGCTTAAAGAATGTCTGAACACT	ORF1a of SARS-CoV-2		
As1_LB	TTGAATTTAGGTGAAACATTTGTCACG			
As1e_FIP	TCAGCACACAAAGCCAAAAATTTAT <u>TTT</u> CTGTGCAAAGGAAATTAAGGAG			
As1e_BIP	TATTGGTGGAGCTAAACTTAAAGCC <u>TTTT</u> CTGTACAATCCCTTTGAGTG			
ORF1a-F3	TCCAGATGAGGATGAAGAAGA	3043-3063 in GeneBank: MT007544.1	Lamb LE et al.[26]	1ª 2 ^b 3 ^c 4 ^d 5
ORF1a-B3	AGTCTGAACAACTGGTGTAAG	3311-3331 in GeneBank: MT007544.1		
ORF1a-LF	CTCATATTGAGTTGATGGCTCA	ORF1a of SARS-CoV-2		
ORF1a-LB	ACAAACTGTTGGTCAACAAGAC			
ORF1a-FIP	AGAGCAGCAGAAGTGGCACAGGTGATTGTGAAGAAGAAGAAGA			
ORF1a-BIP	TCAACCTGAAGAAGAGCAAGAACTGATTGTCCTCACTGCC			
ORF1a-TFIP	AGAGCAGCAGAAGTGGCAC TTTT AGGTGATTGTGAAGAAGAAGAAGA			
ORF1a-TBIP	TCAACCTGAAGAAGAGCAAGAA <u>TTTT</u> CTGATTGTCCTCACTGCC			
GeneE1-F3	TGAGTACGAACTTATGTACTCAT	26232-26254 in GeneBank: MT007544.1	Zhang Y et al.[27]	1° 2 ^b 3 ^c 4 ^d 5
GeneE1-B3	TTCAGATTTTTAACACGAGAGT	26420-26441 in GeneBank: MT007544.1		
GeneE1-LF	CGCTATTAACTATTAACG	Gene E of SARS-CoV-2		
GeneE1-LB	GCGCTTCGATTGTGTGCGT			
GeneE1-FIP	ACCACGAAAGCAAGAAAAAGAAGTTCGTTTCGGAAGAGACAG			
GeneE1-BIP	TTGCTAGTTACACTAGCCATCCTTAGGTTTTACAAGACTCACGT			
GeneE1-TFIP	ACCACGAAAGCAAGAAAAAGAAG			
GeneE1-TBIP	TTGCTAGTTACACTAGCCATCCTTA <u>TTTT</u> GGTTTTACAAGACTCACGT			
GeneN-A-F3	TGGCTACTACCGAAGAGCT	28525-28543 in GeneBank: MT007544.1	Zhang Y et al.[24]	1ª
GeneN-A-B3	TGCAGCATTGTTAGCAGGAT	28722-28741 in GeneBank: MT007544.1		
GeneN-A-LF	GGACTGAGATCTTTCATTTTACCGT	Gene N of SARS-CoV-2		
GeneN-A-LB	ACTGAGGGAGCCTTGAATACA			
GeneN-A-FIP	TCTGGCCCAGTTCCTAGGTAGTCCAGACGAATTCGTGGTGG			
GeneN-A-BIP	AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT			
GeneN-A-TFIP	TCTGGCCCAGTTCCTAGGTAGT <u>ITTT</u> CCAGACGAATTCGTGGTGG			
GeneN-A-TBIP	AGACGGCATCATATGGGTTGCA <u>TTTT</u> CGGGTGCCAATGTGATCT			
N-gene-F3	AACACAAGCTTTCGGCAG	29083-29100 in GeneBank: MT007544.1	Broughton JP <i>et</i> al.[28]	1ª 2 ^b
N-gene-B3	GAAATTTGGATCTTTGTCATCC	29290-29311 in GeneBank: MT007544.1		
N-gene-LF	ТТССТТӨТСТӨАТТАӨТТС	Gene N of SARS-CoV-2		

N-gene-LB	ACCTTCGGGAACGTGGTT				
N-gene-FIP	P TGCGGCCAATGTTTGTAATCAGCCAAGGAAATTTTGGGGGAC				
N-gene-BIP	CGCATTGGCATGGAAGTCACTTTGATGGCACCTGTGTAG				
N-gene-TFI	P CGCATTGGCATGGAAGTCAC <u>TTTT</u> TTTGATGGCACCTGTGTAG				
N-gene-TBⅡ	P TGCGGCCAATGTTTGTAATCAG <u>TTTT</u> CCAAGGAAATTTTGGGGAC				
Gene N2-F3	3 ACCAGGAACTAATCAGACAAG	29136-29156 in GeneBank: MT007544.1	Zhang Y et al.[27]	1ª 2 ^b 3 ^c	
Gene N2-B3	3 GACTTGATCTTTGAAATTTGGATCT	29299-29323 in GeneBank: MT007544.1			
Gene N2-LF	F GGGGGCAAATTGTGCAATTTG	Gene N of SARS-CoV-2			
Gene N2-LE	B CTTCGGGAACGTGGTTGACC				
Gene N2-Fil	P TTCCGAAGAACGCTGAAGCG-GAACTGATTACAAACATTGGCC				
Gene N2-B	P CGCATTGGCATGGAAGTCAC-AATTTGATGGCACCTGTGTA				
Gene N2-TF	IP TTCCGAAGAACGCTGAAGCG <u>TTTT</u> GAACTGATTACAAACATTGGCC				
Gene N2-TB	IP CGCATTGGCATGGAAGTCAC <u>TTTT</u> AATTTGATGGCACCTGTGTA				
ACTB-F3	AGTACCCCATCGAGCACG	287-304 in NM_001101.5	Zhang Y et al.[27]	1° 2 ^b 4 ^d 5 ^e	
ACTB-B3	AGCCTGGATAGCAACGTACA	479-498 in NM_001101.5			
ACTB-LF	TGTGGTGCCAGATTTTCTCCA	Human ACTB mRNA			
ACTB-LB	CGAGAAGATGACCCAGATCATGT				
ACTB-FIP	GAGCCACACGCAGCTCATTGTATCACCAACTGGGACGACA				
ACTB-BIP	CTGAACCCCAAGGCCAACCGGCTGGGGTGTTGAAGGTC				
ACTB-TFIP	GAGCCACACGCAGCTCATTGTA <u>TTTT</u> TCACCAACTGGGACGACA				
ACTB-TBIP	CTGAACCCCAAGGCCAACCGTTTTGGCTGGGGTGTTGAAGGTC				
114	Summary of the above primer sets in optimization phases			<u> </u>	
115	a Phase 1: Primer screening with 30 copies of synthetic SARS-CoV-2 RNA (al	primer sets)			
116	$^{ m b}$ Phase 2: Defining LoDs with 30, 60, 120 and 240 copies of synthetic SARS-	CoV-2 RNA or 0.01, 0.05, 0.25 and 1.25ng of h	uman RNA (ORF1a, E1, I	N-gene N2,	
117	117 and ACTB)				
118	$^{\circ}$ Phase 3: Maximizing sensitivity by primer multiplexing and supplementa	tion GuHCl and/or Betaine with 15 copies of	SARS-CoV-2 synthetic R	NA (ORF1a	
119	and E1)				
120	d Phase 4: Detecting SARS-CoV-2 with extracted RNA from clinical NP samp	les by multiplexing ORF1a and E1 and supplen	nenting GuHCl and Betai	ne (ORF1a	
121	and E1)				

. . .

122 *Phase 5: Detecting SARS-CoV-2 with raw clinical NP samples by multiplexing ORF1a and E1 and supplementing Betaine and Igepal CA-630

123 (ORF1a and E1)

124 Control SARS-CoV-2 RNA

125 Synthetic SARS-CoV-2 viral RNA sequences were ordered from Twist Bioscience (Cat. 126 No. 102019, $1X10^{6}$ RNA copies/µl), and they were non-overlapping fragments of the genome 127 appropriate for each set of primers. The viral RNAs were diluted with DNase/RNase-free water 128 accordingly based on the need of experiments.

129 Clinical nasopharyngeal (NP) samples

Canadian samples: 30 SARS-CoV-2 positive and 36 negative heated-inactivated clinical 130 131 NP samples in Universal Transport Medium (UTM) were provided by the Microbiology Department of Mount Saini Hospital in Toronto Canada. These samples were collected from 132 133 January to July 2020. The sample size was determined based on FDA recommendation regarding 134 development of molecular diagnostic test for SARS-CoV-2 [23]. The samples were kept at -80°C in a Viral Tissue Culture (VTC) laboratory in the Lunenfeld-Tanenbaum Research Institute 135 136 (LTRI), and all the experiments related to these samples were performed in the VTC lab. These 137 samples were surplus diagnostic materials that were analyzed anonymously, and no specific approval from Research Ethics Board (REB) was required. The clinical information regarding 138 these samples was not known. 139

Colombian samples: Two batches of clinical NP swab samples were chosen from the samples collected previously for the Uniandes COVIDA project, and were collected between February 16th and March 29th of 2021. Batch 1: 134 positive and 50 negative samples were reevaluated by qRT-PCR with freshly extracted RNA to confirm SARS-CoV-2 status and sample integrity. With the exclusion of the degraded samples, 41 negative samples and 118 positive samples with Ct values for SARS-CoV-2 Orf1ab from 15 to 36.4 were selected to optimize direct RT-LAMP. Batch 2: 120 positive and 120 negative samples were randomly chosen, and re-

evaluated to confirm SARS-CoV-2 condition and sample quality. With the exclusion of the
invalid, degraded samples, 88 positive and 120 negative samples were selected to test the direct
RT-LAMP assay.

Ecuadorian samples: 21 positive and 21 negative NP swab samples were collected from February to August 2021 in Quito Ecuador. These samples were used to test the optimized RT-LAMP with extracted RNA and raw samples.

153 RNA extraction from clinical NP samples

154 Canadian samples: RNA extraction from clinical NP samples was carried out with 155 miRNeasy Mini Kit (Qiagen, Cat. No. 217004) according to the kit instructions. For all the 156 SARS-CoV-2 positive or negative NP samples, 50µl was aliquoted for RNA extraction, and the 157 extracted RNA was eluted out with 50µl DNase/RNase free water.

Colombian samples: Batch 1: RNA extraction was performed with Quick-RNA viral kit
(Zymo, Cat. No. R1035-E). 100µl of sample_was applied for extraction, and RNA was eluted in
50µl RNAse free water. Batch 2: Extraction was performed using the Nextractor NX-48S
(Genolution), an automated system for rapid DNA/RNA isolation, 200 µl of sample was applied
for extraction. RNAse free water was added to the eluted until it reached the 200 µL.

Ecuadorian samples: RNA extraction was performed with ExtractMe viral RNA kit (Blirt, Cat. No. EM39) following manufacturer's instructions. 100µl of sample was used for extraction, and RNA was eluted out with 30µl RNase free water.

166 Generation of contrived positive NP samples

167 To better evaluate the detection sensitivity of the maximized RT-LAMP with raw NP 168 samples, 12 SARS-CoV-2 positive clinical NP samples from the Canadian cohort were diluted 169 with 12 negative clinical NP samples to create 56 contrived positive NP samples with predicated 170 Ct values between 21.0 and 31.0.

171 **Optimization of RT-LAMP**

172 Before setting up the RT-LAMP experiments, bench surface, racks and pipettes were 173 cleaned with 10% bleach and 70% alcohol to avoid contamination. The main reagents for RT-LAMP were WarmStart colorimetric LAMP 2X Master Mix (NEB, Cat. No. M1800L) and 5mM 174 175 STYO 9 Green Fluorescent Nucleic Acid Stain (Life technologies, Cat. No. S34854). Other 176 reagents for the optimization were GuHCl (Sigma-Aldrich, Cat. No. G3272-25G), 5M betaine (Sigma-Aldrich, Cat. No. B0300-1VL) and Igepal CA-630 (Sigma-Aldrich, Cat. No. I8896). The 177 178 volume for each RT-LAMP reaction was 10µl, including 5µl WarmStart colorimetric LAMP 2X 179 Master Mix, 1µl 10X primer set stock and 1µl template. The remaining volume was filled with 180 H2O or supplements. The RT-LAMP reactions were set up on ice, and were carried out with 384-well plates (ThermoFisher, Cat. No. 4309849) at 65°C using CFX 384 Real-Time System 181 (BIO-RAD) operated with Bio-Rad CFX manager 3.1. The plate reading was set for SYBR green 182 183 reading, and read every 30 seconds, total 120 reads. At the end of the experiments, color images of the 384-well plates were scanned with a Canon photocopier because the commercial RT-184 LAMP kit is designed to produce a change in solution color from pink to yellow with the 185 presence of amplification. In the experiments performed with FluoroPLUM (LSK Technologies 186 187 Inc., Cat. No. SPF), 96-well plates (Luna Nanotech, Cat. No. MPPCRN-NH96W) were used. The optimized RT-LAMP recipes for various conditions were in Table 2. The optimized RT-188

- 189 LAMP assays were evaluated in Colombian and Ecuadorian laboratories with CFX96TM Real-
- 190 Time System (BIO-RAD) using 96-well plates (BIO-RAD, Cat. No. HSP9601).

Templates	Primer concentrations	Supplements ^a	SYTO 9 ^ª	Instruments
Extracted RNA	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	40mM GuHC	1μM	CFX 384 Real-Time
for SARS-CoV-2	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine		System
Extracted RNA	ACTB:	40mM GuHC	1μM	CFX 384 Real-Time
for ACTB	F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	0.5M betaine		System
Raw NP samples	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine	1µM	CFX 384 Real-Time
for SARS-CoV-2	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.25% gepal CA-630		System
Raw NP samples	ACTB:	0.5M betaine	1μM	CFX 384 Real-Time
for ACTB	F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	0.25% gepal CA-630		System
Raw NP samples	ORF1a: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.5M betaine	10µ M	FluoroPLUM
for SARS-CoV-2	Gene E1: F3B3(0.2µM)/FIPBIP(3.2µM)/LFLB(0.4µM)	0.25% gepal CA-630		
Raw NP samples	ACTB:	0.5M betaine	10µ M	FluoroPLUM
for ACTB	F3B3(0.05µM)/FIPBIP(0.4µM)/LFLB(0.1µM)	0.25% gepa CA-630		

191 Table 2. Optimized RT-LAMP conditions

192 ^aAppropriate concentrations for experiments were prepared with DNase/RNase-free water

193 **RT-qPCR**

194 Canadian samples: Before performing experiments, bench surface, racks and pipettes were cleaned with 10% bleach, 70% alcohol and DNAZap (Thermofisher, Cat. No. AM9890). 195 BGI Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 (Cat. No. MFG030018) 196 was applied according to the kit instructions with some modifications. RT-PCR reagents and 197 198 RNA samples were thawed and kept on ice. For each 10µl RT-PCR reaction, 6.17µl SARS-CoV-2 Reaction Mix, 0.5µl SARS-CoV-2 Enzyme Mix, 2.33µl DNase/RNase-free water and 1µl 199 template was loaded to a well of 384-well plate (BIO-RAD, Cat. No. HSP3805). The RT-PCR 200 reaction was carried out with CFX 384 Real-Time System (Bio-Rad Laboratories) operated with 201

202	Bio-Rad CFX Manager 3.1, and the plate reading was set as defined by the kit instructions for all
203	channel reading. A sample was defined as SARS-CoV-2 positive if the Ct for ORF1ab was <
204	37.0. A sample was defined as ACTB positive if the Ct for ACTB was < 35.0.
205	Colombian samples: U-TOP Seasun RT-PCR kit was used to detect viral RNA and

207 positive if Ct value for Orf1ab and/or N gene was \leq 38. The cutoff for RNase P was Ct \leq 38 as 208 well.

human RNase P gene following the kit instructions. A sample was defined as SARS-CoV-2

Ecuadorian samples: The qRT-PCR was performed with an in-house assay with targets in the N and E genes based on the following protocols [29,30]. The SuperScriptTM III PlatinumTM One-Step RT-qPCR Kit (Invitrogen, Cat. No. 12574026) was used to detect specific targets. The cutoff Ct value for the gene E was 30, and 35 for the gene N and human ACTB.

Evaluation of RT-LAMP performance with receiver operating

214 characteristic (ROC) curve analysis

206

For all the positive and negative clinical NP samples confirmed by BGI RT-PCR kit, RT-LAMP TTR or $slope_{20-40}$ was plotted in functions of the true positive rate (Sensitivity) and the false positive rate (1-Specificity) for ROC curve analysis using MedCalc software [31]. The area under the ROC curve (AUC) and cut-off TTR or $slope_{20-40}$ at which the true positive plus true negative rate is highest was calculated. More stringent cutoffs were used in some cases, as indicated in the text, to achieve 100% specificity [23].

221 **Results**

222 Phase 1: Screening primers at a low template copy number

The RT-LAMP reagent used in this study is WarmStart®Colorimetric LAMP 2X Master 223 Mix (NEB, Cat. No. M1800L), and employed four core primers: FIP (forward inner primer), BIP 224 (backward inner primer), F3 (forward primer), B3 (backward primer) to amplify the target 225 region, and two loop primers, LF (loop forward) and LB (loop backward), to enhance reaction 226 speed (Fig 1A). In LAMP reactions, non-specific amplification is common due to *cis* and *trans* 227 228 priming among the six primers [32]. Robust performance of RT-LAMP requires thorough optimization of the six primers over a wide range of concentrations [33]. Including a "TTTT" 229 linker between the F1c and F2 as well as B1c and B2 regions of FIP and BIP (Fig 1A) can 230 231 improve sensitivity [25,34]. Thus, to optimize SARS-CoV-2 detection, we tested 14 primer sets (7 with and 7 without a TTTT insert), which included 12 targeting SARS-CoV-2 and 2 for 232 human β -actin (ACTB, Fig 1B and Table 1). The pilot screen tested 16 different primer 233 concentrations, representing four different primer ratios, with four replicates per test condition 234 (Fig 1C). Accurate estimation of sensitivity and specificity requires more replicates, but we 235 limited the pilot screen to quadruplicates in view of the large survey matrix (14 primers x 16) 236 conditions x 4 replicates = 896 reactions). This approach provided initial approximate 237 sensitivity/specificity estimates to select primers and primer amounts for the next test phase. 238

239

Fig 1. Screening primer performance at a low copy number of SARS-CoV-2 RNA. (A) A schematic showing a DNA template amplified by LAMP and the primers targeted to the regions

242 in the template. (B) Location of the 7 target regions for the 14 primer sets in the SARS-CoV-2 243 genome (NC 045512.2, [35]). The indicated target region is that amplified by the outer F3 and 244 B3 primers. (C) Matrix of test conditions. Each primer set was tested with the indicated primer 245 molar ratio (black), and primer concentrations (blue). A total of 16 conditions were tested for each of the 14 primer sets, with 4 replicates per condition. Other reaction reagents are indicated 246 in red. (D) Screening results for primer Gene E1. Top panel: For the indicated primer mixes (X-247 248 axis), red and blue bars indicate TTR using 30 copies of positive control SARS-CoV-2 RNA (TTR^{PC}) or no template (TTR^{NTC}), respectively. Red and blue circles indicate sensitivity and 249 specificity, respectively. Bottom left graph shows an example of the fluorescent signal obtained 250 with STYO 9 dye over the 60 minute reaction period for PC (red) or NTC (blue – undetected) 251 using the indicated Gene E1 primer mix. Green line: threshold to designate TTR. Bottom right 252 253 panel shows an example of the phenol red colour at 60 minutes. (E and F) Screening results of 254 primer ORF1a (E) and human ACTB (F); format as in (D). (G) Summary of the best two primer concentrations for the top performing four primer sets with adequate performance based on 255 256 sensitivity, specificity and TTR. NTC, no template control; PC, positive control (30 copies of SARS-CoV-2 RNA); Sensitivity, the percentage of PC replicates with amplifications; 257 258 Specificity, the percentage of NTC replicates without amplifications; RFU, relative fluorescence 259 units; TTR, time to results (minutes), the time point that the RFU curve crossing the fluorescent 260 threshold; Error bars represent mean \pm standard deviations.

261

To develop a sensitive RT-LAMP assay, we used only 30 copies of synthetic SARS-CoV-2 RNA (Twist Bioscience) in these primer comparisons. To optimize RT-LAMP for ACTB, we used 5ng human RNA. RT-LAMP reactions were carried out at 65°C in a

265 thermocycler. 1 µM SYTO 9 green fluorescent dye was used to track the time to result (TTR) in 266 min., deemed as the point at which the RFU (relative fluorescence units) curve crosses the fluorescent threshold (green line, Fig 1D). TTR values were plotted together with sensitivity (% 267 268 confirmed positives/ positives tested) and specificity (% confirmed negatives/negative controls tested). The commercial RT-LAMP kit also contains phenol red, which changes from pink to 269 yellow with successful amplification, thus we also recorded color at the end of each experiment. 270 271 Primer concentration and type affected the specificity of RT-LAMP reactions considerably (Figs 272 1D-1F and S1 Fig), and from this survey the best two primer concentrations of the four topperforming viral primer sets and the best ACTB primer sets were prioritized for Phase 2 (Fig 273 The selected primer sets included Gene E1, N-gene, Gene N2, and ORF1a, which 274 1G). displayed excellent TTR (~10-14 min), sensitivity (all 100% except Gene N2) and specificity (all 275 276 100%). The "TTTT" linker did not improve or impaired performance for 6/7 of the SARS-CoV-277 2 and the ACTB primers, and although it did improve detection with Gene N-A primers, these 278 remained inferior to the four selected viral primers (S1A Fig). The two best concentrations for 279 ACTB primers were much lower than those of the SARS-CoV-2 primers, and also exhibited a 280 lower TTR than viral primers (Figs 1F and 1G).

281 Phase 2: Selection of primers with optimal LoD and specificity

In Phase 2, we increased replicates to 10 (from 4), and assessed 4 (rather than 1) viral template amounts (30, 60, 120, 240 copies). We also assessed four template amounts for ACTB primers (0.01, 0.05, 0.25 or 1.25 ng human RNA). In total, therefore, Phase 2 involved 400 reactions (5 primer sets x 2 primer concentrations x 10 replicates x 4 template concentrations). The LoD is commonly defined as the concentration of analyte that can be detected in 95% of

287 replicates [36], but as we used 10 replicates in this phase, we defined LoD as the lowest copy 288 number at which sensitivity was 100% after 30 min. Specificity was calculated using the no 289 template control (NTC) reactions at both 45 and 60 min. time points, which was used together 290 with the LoD to stratify primer sets (Fig 2A and S2 Fig). ORF1a, E1 and N2 primers at the 0.2/3.2/0.4 uM F3B3/FIPBIP/LFLB ratio were the top performers, with LoDs of 120, 240 and 291 240 copies, respectively and 100% specificity at 45 min (Fig 2A and S2D, S2A and S2C Figs). 292 293 The alternate F3B3/FIPBIP/LFLB ratio for these primers also performed well, but the LoD 294 and/or specificity was marginally weaker (Fig 2A and S2D, S2A and S2C Figs). The N-gene primer set LoDs were similar to the E1 and N2 primers, but specificity was slightly worse at 60 295 min (Fig 2A and S2B Fig), thus we excluded it from Phase 3. The LoD for the ACTB primers 296 was 100% at all four template concentrations. However, ACTB primer specificity was 100% vs. 297 298 80% at both 45 and 60 min with the 0.05/0.04/0.1 uM FB3/FIPBIP/LFLB ratio (Fig 2B and S2E Fig), which was thus selected for Phase 3. 299

300

Fig2. Evaluation of the optimized primer concentrations based on limit of detection and specificity. (A) ORF1a, Gene E1, Gene N2 and N-gene primers were assessed at the indicated conditions. Each condition was evaluated with 10 replicates. (B) ACTB primers were evaluated under the indicated conditions. Sensitivity, the percentage of replicates with SARS-CoV-2 RNA or human RNA showing amplifications; Specificity, the percentage of no template controls without amplifications; TTR, time to results (minutes); LoD, limit of detection; Error bars represent mean ± standard deviations.

308

309 Phase 3: Maximizing sensitivity and specificity with primer 310 multiplexing and supplements

Multiplexed LAMP assays can be used to simultaneously test for multiple pathogens by 311 labeling primers for different pathogens with different fluorophores [37,38]. Here, we tested 312 313 whether multiplexing the best primer sets from Phase 2 (ORF1a, E1 and N2) improves detection sensitivity of SARS-CoV-2. To reveal differences in sensitivity, we used only 15 copies of viral 314 315 template, and ran 10 replicates each to compare E1, N2 or ORF1a primer sets alone, or each of 316 the three possible pairings (Fig 3A and S3A Fig). To calculate sensitivity, only fluorescent 317 signals that appeared within 30 mins were counted, whereas specificity of fluorescent NTC reactions were assessed for 60 min. Color reactions were also visually inspected at 60 min. At 15 318 template copies, the N2 primer sets alone failed, while the E1 or ORF1a primer sets alone 319 320 exhibited < 50% sensitivity, and only the latter provided 100% specificity (Fig 3A and S3A Fig). 321 Notably, each of the three primer set pairings improved sensitivity, and the best success rate of 70% success was achieved with the E1 + ORF1a combination, with a mean TTR of < 15 min, 322 and 100% specificity (Fig 3A). At 60 min, 9/10 template reactions (90%) generated the 323 324 anticipated color change with the E1 + ORF1a combination, while 10/10 NTC reactions remained red (S3B Fig). This dual target primer mix was then taken forward to test whether 325 326 various additives might further improve performance.

327

Fig 3. Effect of primer multiplexing and supplements. (A) Evaluation of RT-LAMP performance with the indicated primer multiplexing. RT-LAMP reactions were carried out with 15 copies of SARS-CoV-2 RNA at the optimized concentration for each primer set (see Fig 2A

in bold). (B) Evaluation of RT-LAMP performance with 40mM GuHCl and/or 0.5M betaine. Reactions were performed with multiplexed Gene E1 and ORF1a primers. (C) LoD assessment of the best RT-LAMP condition with the indicated copy numbers of SARS-CoV-2 RNA. (D) Fluorescent readouts and color changes of the reactions in (C) at 60 minutes. Each condition was evaluated with 10 replicates. NTC, no template control; TTR, time to results; RFU, relative fluorescent units; Error bars represent mean \pm standard deviations.

337

A recent study demonstrated that 40 mM of the denaturing agent guanidine hydrochloride 338 (GuHCl) improves the sensitivity of detection of synthetic SARS-CoV-2 RNA, although patient 339 340 samples were not tested [27]. A separate study reported that GuHCl did not improve results with 341 patient samples [39]. Betaine, which improves PCR amplification of GC-rich DNA sequences [40], can also enhance RT-LAMP [41,42]. Thus, we tested whether GuHCl and/or betaine 342 improves sensitivity with the E1 + ORF1a primer combo with 15 copies of viral template. In the 343 344 unmodified reaction, sensitivity was, as before, 70%, while specificity at 60 min dropped in this experiment from 100% to 90% (c.f. Fig 3A vs. Fig 3B and S3C Fig), although this aberrant 345 346 signal appeared beyond 50 min., well after the 30 min. cutoff used to define sensitivity (S3C 347 Fig). Adding GuHCl alone, or more so Betaine alone, reduced sensitivity, but combining GuHCl + Betaine elevated sensitivity to 80%, and in all three of these conditions, specificity was 100% 348 349 (Fig 3B, S3C and S3D Figs). With this optimized condition, we ran 10 replicates on 4 viral 350 template amounts (7.5, 15, 20, 25 copies), which defined the LoD as 20 copies (2 copies/ μ) 351 (Figs 3C and 3D). One out of 10 NTC reactions generated an aberrant signal, but again at 352 beyond 50 min. (Fig 3D). Thus, the combination of E1 and ORF1a primers together with GuHCl and Betaine provided the most sensitive detection of synthetic SARS-CoV-2 RNA. 353

Phase 4: Optimized RT-LAMP is comparable to a clinical RT-PCR test with extracted RNA

To test the efficiency of the maximized RT-LAMP in detecting SARS-CoV-2 RNA from 356 clinical patient samples, we tested 30 positive and 36 negative NP samples. RNA was extracted 357 358 and RT-PCR performed with the BGI RT-PCR kit, which is used in the clinic to detect SARS-CoV-2 ORF1ab and human ACTB [43,44]. Ct values correlated well with clinical Ct values from 359 360 other detection methods in the positive samples (Fig 4A), and no SARS-CoV-2 was detected in the 36 negative samples (not shown). We then ran RT-LAMP with the Phase-3-optimized 361 conditions and plotted a receiver operator characteristic (ROC) curve of true positive rate (TRP) 362 vs. false positive rate (FPR) ranked on TTRs to evaluate performance. Random assignment of 363 test results generates a diagonal line from 0,0 to 100,100 with an area under the curve (AUC) of 364 0.5, whereas a perfect test generates vertical line from 0.0 to 0.100 and an AUC of 1.0. RT-365 366 LAMP was comparable to the BGI RT-PCR assay, with an AUC of 0.971 (95% CI: 0.896 – (0.997) (P < 0.0001). The TTR at which the TPR + true negative rate (or 1-FPR) is highest was 367 368 13.2 minutes, and at that cutoff the sensitivity and specificity of RT-LAMP was 90% (95% CI: 369 73.5% - 97.9%) and 100% (95% CI: 90.3% - 100%), respectively. The latter satisfies a recommendation from the FDA that tests should exhibit 100% specificity [23]. Of the 3/30 370 371 positive samples that were not detectable by RT-LAMP, all were borderline RT-PCR positives 372 with Ct values of 36.0 – 37.0 (Fig 4C). RT-LAMP successfully detected human ACTB within 20 373 min in all positive and negative samples (Figs 4D and 4E). Instead of using a thermocycler and a 374 fluorescent readout, we re-ran RT-LAMP with the above 30 positive and 36 negative samples at 375 65°C in a water bath for 25 minutes using the end-point colorimetric method, and observed

similar sensitivity and specificity (S4A Fig). Thus, with patient-extracted RNA, the optimized RT-LAMP reaction is essentially as sensitive as the gold standard RT-PCR assay used in the clinic, and can be performed using a method (heat source and detection) that is appropriate for low-resource settings.

380

381 Fig 4. Comparison of RT-LAMP and BGI RT-PCR with extracted RNA from clinical NP samples. (A) Correlation of Ct values with BGI RT-PCR kit vs. other indicated RT-PCR 382 reagents in 30 SARS-CoV-2 positive clinical NP samples. (B) ROC curve evaluating RT-LAMP 383 performance with 30 positive and 36 negative Canadian clinical samples based on the results of 384 BGI RT-PCR kit. TPR: true positive rate; FPR: false positive rate. TTR ≤ 13.2 ' was defined as 385 386 the cut-off to distinguish positive from negative samples with 90% detection sensitivity and 100% specificity. (C) Distribution of RT-LAMP TTRs against BGI RT-PCR Ct values for 30 387 positive and 36 negative clinical NP samples. BGI RT-PCR and RT-LAMP positives were 388 389 defined by Ct < 37.0 and TTR \leq 13.2' respectively. (D) Distribution of human ACTB TTRs. (E) Representative fluorescent readouts and phenol red colour with RT-LAMP reactions at 60 390 391 minutes in (C and D) with the clinical NP samples. (F) ROC curve evaluating RT-LAMP 392 performance with 21 positive and 21 negative NP samples from Ecuador. TTR \leq 41' was defined as the cut-off to distinguish positive from negative samples with 100% specificity and sensitivity. 393 (G) Distribution of RT-LAMP TTRs vs. RT-PCR Ct values for gene E with samples in (F). RT-394 PCR and RT-LAMP positives were defined by $Ct \le 30.0$ for gene E and TTR $\le 41'$ respectively. 395 396 (H) Distribution of human ACTB TTRs of samples in (F).

397

398	To further validate the LAMP assay, it was evaluated in the National Institute of Public
399	Health Research (INSPI) in Ecuador, which employed different clinical protocols for RNA
400	extraction and qRT-PCR to diagnose SARS-CoV-2 infection [29,30]. RT-LAMP was performed
401	with 20 positive and 21 negative NP swab samples. ROC curve analysis indicated an AUC of 1.0
402	(95% CI: 1.000 – 1.000) ($P < 0.0001$), and defined the cutoff TTR as 41 minutes. With this
403	cutoff TTR, the assay exhibited 100% sensitivity (95% CI: 83.9% - 100%) and 100% specificity
404	(95% CI: 84.5% - 100%) (Figs 4F and 4G). Human ACTB was detected in all the samples within
405	35 minutes (Fig 4H). Thus, the optimized RT-LAMP performed robustly on extracted patient
406	RNA independent of location or RNA extraction and RT-PCR methods.

407 Phase 5: SARS-CoV-2 detection in raw clinical NP samples without

408 **RNA extraction**

The above tests require access to appropriate resources to purify RNA. Next, therefore, 409 we utilized the clinical NP samples assessed in Phase 4 to determine whether RT-LAMP could 410 411 be used as a PoC test for direct detection of SARS-CoV-2 without RNA extraction. We utilized the E1 + ORF1a dual primer set and compared amplification with no supplements or the addition 412 413 of betaine and GuHCl alone or together. 1 µl of raw patient sample in Universal Transport 414 Medium (UTM) was assessed per 10 µl reaction. RT-LAMP successfully detected human ACTB in all samples within 35 min across all the tested conditions, except for Betaine-alone 415 416 supplementation where the TTRs of one positive and one negative sample were between 40-45 minutes (S5A Fig). To optimize viral RNA detection, we initially assessed four conditions 417 (labeled #2-4 in Fig 5A), which included no supplements, GuHCl alone, Betaine alone, or 418 419 GuHCl + Betaine and employed ROC curves to identify valid tests. Using a cutoff of P < 0.001,

recommended for comparing ROC curves [45], only Betaine (P < 0.0001) generated an AUC (0.742) that was significantly different from a random test (Fig 5A). Comparing the ROC curves for each condition, the only significant difference was between Betaine alone and GuHCl alone (Fig 5A). These results differed from those obtained with purified RNA, where combining GuHCl and Betaine created a high-performance assay (Figs 3 and 4). These data underscore the importance of optimizing a PoC assay with raw clinical samples.

426

Fig 5. Direct RT-LAMP on raw clinical NP samples without RNA extraction. (A) ROC 427 curves evaluating RT-LAMP performance on 30 positive and 36 negative clinical NP samples 428 with the indicated supplements. 0.5M betaine + 0.25% Igepal CA-630 in green; 0.5M betaine in 429 430 red; No supplements in pink; 40mM GuHCl + 0.5M betaine in light blue; 40mM GuHCl in black. 1µl of raw samples (without any sample processing) was applied to RT-LAMP reactions, 431 and the reactions were carried out with multiplexing primers for Gene E1 and ORF1a. 432 Significance values were calculated with MedCalc software for ROC curve analysis. TTR^{*} 433 indicates the cutoff providing optimal sensitivity and specificity. (B) Distribution of the RT-434 435 LAMP TTRs vs. BGI RT-PCR Ct values with the indicated supplements. Dotted lines indicate 436 cutoffs. (C) Representative fluorescent readouts of RT-LAMP with 0.5M betaine and 0.25% Igepal CA-630. (D) Sensitivity of RT-LAMP at the indicated Ct ranges. Left panel, Clinical NP 437 samples. Right panel, Contrived positives generated by diluting clinical NP positives with 438 negative NP samples. 439

440

441 Although ROC curve analyses confirmed that Betaine supplementation generates a useful test, sensitivity was only 43.3% (Fig 5A). As a fifth condition (labeled #1 in Fig 5A), we 442 modified the Betaine-alone condition by adding 0.25% Igepal CA-630, a detergent that enhances 443 444 RT-qPCR detection of influenza virus in MDCK cells without RNA extraction [46]. Specificity was 100% in both cases, but sensitivity and AUC increased to 53.3% and 0.771, respectively 445 (Fig 5A). However, this was not significantly different from Betaine alone (sensitivity 43.3%, 446 447 AUC 0.742), and was still well below the 90% sensitivity and AUC of 0.971 observed with purified RNA (c.f. Figs 4B and 5A). Comparing RT-PCR Ct values on purified RNA to RT-448 LAMP TTR values on raw samples illustrated that the latter performed best on high titer (low Ct) 449 samples (Figs 5B and 5C). Plotting the Ct values of false negatives and true positives with 450 Betaine + Igepal RT-LAMP clarified this bias; 100% (15/15) of samples with $Ct \le 26.6$ were 451 452 detected, 25% (1/4) sample Ct from 27.1 - 30 were detected, and no samples (0/11) with Ct > 30 453 were detected (Figs 5C and 5D). In all samples, human ACTB was detected within 30 minutes 454 (S5A Fig).

To better define sensitivity around the approximate cutoff, we diluted high titer positives 455 456 with negative patient samples to generate a series of contrived positives with predicted Ct values in the desired range. Direct RT-LAMP detected ACTB in all cases (S5B Fig). Viral RT-LAMP 457 indicated a sensitivity of 100% (95% CI: 67.6% - 100%), 80% (95% CI: 58.4% - 91.9%) and 458 459 31.8% (95% CI: 16.4% - 52.7%) for samples with $Ct \le 25$, 25 - 27.2, and 27.2 - 29.2, respectively, and all samples with a Ct \ge 30.0 were false negatives (Fig 5D). In these Canadian 460 samples, Ct values of 25, 27 and 30 corresponded to 7.9 X 10⁶, 2.5 X 10⁶ and 3.2 X 10⁵ copies of 461 462 SARS-CoV-2 per mL of raw NP samples respectively. Thus, the optimized RT-LAMP assay 463 used directly on 1 µl of NP sample may be a useful screening tool to identify infectious

individuals bearing high viral loads [10–12], but should not be used to definitively rule outinfection.

To test robustness, the assay was evaluated in the diagnostics laboratory, Universidad de 466 Los Andes (Uniandes), Colombia, with 118 positive and 41 negative clinical NP samples. To 467 468 account for degradation during storage, Ct values were re-assessed with the U-TOP Seasun kit (one-step RT-PCR). To establish a TTR cutoff for use in this setting we assessed 41 negatives 469 and 118 positives, most of which had Ct values < 30. ROC curve analysis generated an AUC of 470 $0.916 \ (P < 0.0001)$, and defined the cutoff TTR as 25 minutes with 100 % (95% CI: 91.4% -471 472 100%) specificity, recommended by the FDA [23] (Fig 6A). With this cutoff TTR, sensitivity on these selected samples was 49.2% (95% CI: 40.3% - 58.1%) (Fig 6A). As with the Canadian 473 474 samples, plotting TTR vs. Ct showed more efficient detection in high titer (lower Ct) samples (Fig 6B). Sensitivity was 91.4% (95% CI: 80.1% – 96.6%) at Ct < 23, but dropped to 39.1% 475 476 (95% CI: 22.2% – 59.2%), 23.8% (95% CI: 10.6% – 45.1%), and 6.7% (95% CI: 0.3% – 29.8%) for samples with Ct 23 - 25, 25 - 27, and 27 - 30, respectively, and all samples with a Ct > 30 477 were false negatives (Fig 6B). The assay detected ACTB in all 159 samples within 40 minutes 478 479 except 3 positive samples (Fig 6C).

480

Fig 6. Direct RT-LAMP on raw clinical NP samples of Colombia and Ecuador. (A) ROC curve evaluating the optimized direct RT-LAMP performance on 118 positive and 41 negative clinical NP samples from Colombia. (B) Distribution of the RT-LAMP TTRs vs. U-TOP Seasun RT-PCR Ct values for Orf1ab, and the sensitivity of RT-LAMP at the indicated Ct intervals with samples in (A). (C) Distribution of ACTB TTRs of samples in (A). (D) Plot of TTRs vs. Ct

486	values in a simulation RT-LAMP test with randomly chosen Colombian samples, and the
487	sensitivity at the indicated Ct intervals with these samples. (E) ROC curve analysis validating the
488	simulation RT-LAMP test in (D). (F) Distribution of ACTB TTRs of samples in (D). (G) ROC
489	curve analysis of the direct RT-LAMP with 21 positive and 21 negative NP samples of Ecuador.
490	(H) Distribution of the direct RT-LAMP TTRs vs. RT-PCR Ct values for E gene, and the
491	sensitivity at the indicated Ct values for samples in (G). (I) Distributions of ACTB TTRs of
492	samples in (G). Dotted lines in distribution graphs indicate cutoffs.

493

Using the above TTR cutoff, a simulation test of direct RT-LAMP was then performed 494 with 208 randomly chosen samples (88 positive, 120 negative). We observed 100% specificity 495 496 (95% CI: 96.9% - 100%) at the preselected TTR cutoff, while sensitivity was again dependent on Ct values, varying from 90.0% (95% CI: 69.9% – 98.2%), 83.3% (95% CI: 43.6% – 99.1%), 497 85.7% (95% CI: 48.7% – 99.3%), for samples with Ct \leq 23, 23 – 25, and 25 – 27 respectively, 498 499 but dropping to 6.7% (95% CI: 0.3% - 29.8%) when Ct was 27-30, and all samples with a Ct > 30 were false negatives (Fig 6D). Overall, sensitivity in this setting with these randomly selected 500 501 samples was only 36.4%, below the 53.3% observed in the Canadian lab (Table 3). The 502 performance of the assay in this simulation test was validated by ROC curve analysis with an AUC 0.854 (P < 0.0001) (Fig 6E). Human ACTB was detected in all 208 samples within 40 503 504 minutes except for 5 positive and 8 negative samples (Fig 6F).

Finally, direct RT-LAMP was also tested in INSPI laboratory in Ecuador with 21 positive (all reconfirmed Ct values \leq 30 for Gene E) and 21 negative NP samples. ROC curve analysis confirmed performance with an AUC 0.882 (95% CI: 0.770 – 0.994) (P < 0.0001), sensitivity

26

71.4% (95% CI: 50.0% - 86.2%) and specificity 100% (95% CI: 84.5% - 100%) at the TTR cutoff defined in this setting of 45 minutes (Fig 6G). As with the Canadian and Colombian data sets, sensitivity was higher in samples with low Ct values (Fig 6H). ACTB was detected within 45 minutes in most of the samples (Fig 6I). Together, these multi-centre studies suggest that this direct RT-LAMP assay has utility as a PoC test to screen contagious individuals with high viral loads to limit transmission. These data also highlight the real-world fluctuations in sensitivity associated with distinct detection platforms in different locations.

515 **Phase 6: Direct RT-LAMP with a PoC device: FluoroPLUM**

516 The above direct RT-LAMP protocol removes the need for RNA extraction, but requires 517 a thermocycler. Thus, to further aid PoC testing, we tested a low cost combined incubator and plate reader, FluoroPLUM, developed by LSK Technologies Inc. This device incubates the 518 519 reaction chamber up to 65° C and utilizes royal blue LEDs (Luxeon, 440 nm ~ 455 nm), a long 520 pass filter with 515 nm cutoff, and a camera to track change in green channel fluorescence 521 intensity of DNA-bound SYTO 9. Once a 96-well sample plate is loaded on the tray, the device 522 automatically detects wells of interest from captured images and monitors the reaction for 50 523 minutes. Based on a digital map of the multiwell plate used for the experiments, PLUM software 524 automatically displays graphed results on the screen at the end of the assay (Figs 7A and 7B). It is portable and can be operated on any global power supply using the correct plug adaptor, or a 525 526 portable 12V 10A battery (8-9 h), making it ideal for PoC testing. To interpret the results in 527 FluoroPLUM, we used linear regression to measure "slope₂₀₋₄₀" (Fig 7C), as it provided easier 528 differentiation among positive and negative samples compared to TTR used in thermocyclers. Slope₂₀₋₄₀ is calculated using all the data points between 20 - 40 mins, during which 529

530 amplification typically occurs in direct RT-LAMP (Figs 5A-5C and 7A). An increase in the 531 concentration of SYTO 9 (10µM) performed better in FluoroPLUM reactions than lower 532 concentrations (S6 Fig and Table 2) and, accordingly, was used in all subsequent assays. From 533 the same group of raw Canadian clinical NP samples as before, we determined slope₂₀₋₄₀ for 30 positive and 29 negative samples and ran ROC analysis. FluoroPLUM generated an AUC of 0.79 534 (P < 0.0001), comparable to data obtained with a thermocycler (c.f. Figs 5A and 7D). The 535 536 $slope_{20-40}$ at which sensitivity + specificity is highest was 0.0004, and at that cutoff the sensitivity 537 and specificity of RT-LAMP was 70% and 86%, respectively. The latter does not meet FDA guidelines of 100% specificity regarding SARS-CoV-2 molecular test development [23], so we 538 used $slope_{20-40} > 0.0048$ to define positives, as no false positives were detected above this cutoff. 539 At this cutoff, sensitivity was 36.7% (95% CI: 21.9% to 54.5%), and specificity was 100% (95% 540 541 CI: 88.3% to 100%). Sensitivity was 100% (95% CI: 67.6% - 100%) or 76.9% (95% CI: 49.7% -542 91.8%) for samples with Ct < 22.5 or Ct < 25 respectively, and fell to only 6.3% at Ct > 25 (Fig 7E). In these raw samples, Ct at 22.5 and 25 reflects viral titer at 5.0 X 10^7 and 7.9 X 10^6 543 544 copies/mL respectively. These results were consistent with reaction color changes visualized at the end of the experiment (Figs 7G and 7H). The assay efficiently detected human ACTB with 545 98.3% sensitivity (58/59) (Figs 7F and 7H). Thus, the portable FluoroPLUM instrument, which 546 547 can be deployed in PoC settings, performs similarly to the thermocyclers used in a diagnostic lab. 548

549

Fig 7. Direct RT-LAMP with FluoroPLUM. (A) FluoroPLUM readout of RT-LAMP assessment of the boxed wells in (B). Each solid line represents one reaction, monitored for 45 minutes, and quantified as 'PLUM reading units'. N1A5 (red) and N1V5 (green) are examples of

553 positive and negative samples, respectively. The red dash line is the average reading of all the 554 wells in the plate (B) for the first 3 minutes. (B) Image of RT-LAMP reactions at the end of the 555 experiment. (C) Slope₂₀₋₄₀ for the two reactions indicated in (A) and (B). (D) ROC curve 556 evaluating FluoroPLUM performance using slope₂₀₋₄₀ values. (E) Distribution of slope₂₀₋₄₀ values vs. BGI RT-PCR Ct values. Dotted lines indicate cutoffs (RT-LAMP: $slope_{20-40} > 0.0048 =$ 557 positive, RT-PCR: Ct < 37 = positive). (F) Distribution of $slope_{20-40}$ for human ACTB in clinical 558 559 NP samples. (G) Images of color changes for the 30 positive (red) and 29 negative (blue) clinical 560 NP samples. Asterisks: three samples with no amplification of ACTB, two of which showed amplification in a repeat run (bottom image). (H) Sensitivity with end-point data in (G). 561

562

563 **Discussion**

Through stepwise optimization of a commercially available RT-LAMP reagent, we 564 565 developed a SARS-CoV-2 RT-LAMP assay with the potential to be deployed as a PoC test for 566 infectious cases. First, we systemically screened the performance of 7 primer sets (6 for SARS-CoV-2 and 1 for human ACTB), as well as different "TTTT" linker formats, over a wide range 567 568 of concentrations using a low copy number synthetic SARS-CoV-2 target RNA. Based on sensitivity, specificity and TTR, Gene E1, Gene N2 and ORF1a primer sets were chosen with an 569 570 ideal concentration for each primer. The ideal concentration for an ACTB primer set was also finalized. We found tremendous variability in performance and ideal concentrations across 571 572 different primer sets, underscoring the value of the optimization matrix [33]. Multiplexing Gene 573 E1, N2 and/or ORF1a primer sets as well as supplementing reactions with GuHCl and betaine 574 improved sensitivity. The optimized RT-LAMP (multiplexed primers for Gene E1 and ORF1a

575 plus supplementation with 40mM GuHCl and 0.5M betaine) decreased the LoD from 240 copies 576 with the original reagents to 20 copies of SARS-CoV-2 viral RNA per reaction. This 577 improvement has diagnostic significance because each 10-fold increase in the LoD of a COVID-578 19 viral diagnostic test is expected to increase the false negative rate by 13% [47]. Mapping the optimal primer sets onto sequences of the dominant variants delta and omicron 579 580 (https://covariants.org/variants) revealed no mismatches. Furthermore, the primer sets target 581 different regions of viral genome, fulfilling an FDA recommendation that molecular tests detect 582 more than one viral genome region [48].

583 With extracted RNA from clinical NP swab samples, we found the optimized RT-LAMP test was comparable to the BGI RT-qPCR kit, a diagnostic RT-PCR test with top detection 584 sensitivity approved by the FDA [44,49]. ROC curve analysis showed that the AUC was 0.971 585 (P < 0.0001) with 90% sensitivity and 100% specificity. The BGI RT-qPCR protocol defines 586 587 samples with Ct < 37 for ORF1ab as SARS-CoV-2 positive. RT-LAMP successfully detected 588 SARS-CoV-2 RNA in all positives except three with 36 < Ct < 37, and detected human ACTB in 589 all samples. Notably, the RT-LAMP test takes less than 20 minutes compared with 2 hours for 590 RT-qPCR, and can be performed with a 65°C water bath. For low-resource settings, this reduces 591 the capital investment for RT-qPCR infrastructure (~\$25,000), has the potential to bring high fidelity molecular diagnostics to distributed community testing, and reduces the per test cost 592 from ~\$25 USD (RT-qPCR) to ~\$2.40 (RT-LAMP). 593

The same assay tested in Ecuador presented an AUC 1.0 with ROC curve analysis, 100% sensitivity and specificity, and detected human ACTB in all the samples. The assay, however, took about 40 minutes, which may reflect differences in reagent sources, sample handling, as well as instrument models. Thus it is important to optimize the cutoff TTR based on different

testing conditions. Nonetheless, the strong performance with extracted RNA samples in different countries suggests that RT-LAMP could be deployed when RT-qPCR is limited because of a lack of reagents and/or thermocyclers. Indeed, the WHO considers diagnostic tests with sensitivity \geq 80% and specificity \geq 97% as suitable replacements for laboratory-based RT-PCR if the latter cannot be delivered in a timely manner [50].

Although RT-PCR with purified RNA is the gold standard to confirm SARS-CoV-2 603 infection, a major limitation is its long turnaround time, especially outside of larger urban 604 centers, compromising test efficacy in terms of timely self-isolation and contact tracing. Rapid 605 606 and economical PoC tests for SARS-CoV-2, together with masking and social distancing, are 607 necessary to stop community transmission of the disease [51,52]. With this in mind and recognizing that minimum sample manipulation is essential for PoC tests [15], we next 608 609 optimized RT-LAMP for raw Canadian NP swab samples without RNA extraction. The best 610 condition used multiplexed Gene E1 and ORF1a primers and supplementation with 0.5M betaine 611 and 0.25% Igepal CA-630. In < 32 mins, the optimized RT-LAMP detected samples with Ct \leq 25 (viral load \ge 7.9 X 10⁶ copies/mL) with 100% sensitivity, samples with 25 < Ct \le 27.2 (viral 612 load: 2.6 X 10^6 - 7.9 X 10^6 copies/mL) with 80% sensitivity and samples with 27.2 < Ct \leq 29.2 613 (viral load: 5.0 X 10⁵ - 2.0 X 10⁶ copies/mL) with 31.8%. However, this direct test failed to 614 detect SARS-CoV-2 in samples with Ct \ge 30 (viral load \le 3.2 X 10⁵ copies/mL). For all the 615 samples, the RT-LAMP detected human ACTB in less than 30 minutes. Detection of high titer 616 617 samples was also demonstrated in labs in Colombia and Ecuador. In the former, an initial survey of 41 negative and 118 positive selected samples defined a cutoff TTR of 25 minutes, then a 618 619 simulation detection test with 88 positive and 120 negative randomly chosen samples displayed 620 100% specificity, and 90% sensitivity with high titer (Ct \leq 23) samples. Overall, sensitivity in

the Bogota study was 33.4%, below the 55% seen in the Toronto lab. Human ACTB was 621 detected in more than 95% of the samples within 40 minutes. A smaller test in Ecuador with 21 622 positive (Ct < 30) and 21 negative samples indicated a cutoff TTR of 45 minutes, longer than 623 624 those of the Canadian and Colombian labs. These results underscore the importance of optimizing RT-LAMP in different locations. Variability may arise from changes in reagents, the 625 logistics of sourcing reagents (e.g. international shipping, time in customs), equipment and 626 627 personnel, and/or heat-inactivation of clinical samples (Table 3). However, taken together, RT-LAMP brings the potential for deploying molecular testing broadly and, even with a detection 628 threshold limit of Ct 27, could provide significant gains for public health efforts to contain 629 infection. 630

631

Studies	Samples	Cts	Specificity	Overall sensitivity	Ct-specific sensitivity	Human gene	Sample pretreatment
This study	NP samples	19.0 - 36.9	100%	53.3%	100%, Ct ≤ 26.6	АСТВ	56⊡C, 30 min*
Toronto, Canada	30 positive	Cutoff ≤ 37			0%, Ct > 30		
	36 negative						
This study	NP samples	15.9 - 36.0	100%	49.2%	91.4%, Ct < 23.0	АСТВ	None
Bogota, Colombia	118 positive	Cutoff ≤ 38			0%, Ct > 30		
Optimization test	41 negative						
This study	NP samples	15.6 - 37.2	100%	36.4%	90%, Ct ≤ 23.0	АСТВ	None
Bogota, Colombia	88 positive	Cutoff ≤ 38			0%, Ct > 30		
Simulation test	120 negative						
This study	NP samples	16.3 - 28.9	100%	71.4%	91.7%, Ct < 20	АСТВ	None
Quito, Ecuador	21 positive	Cutoff ≤ 30					
	21 negative						
This study	NP samples	19.0 - 36.9	100%	36.7%	100%, Ct < 22.5	АСТВ	56⊡C, 30 min*
Toronto, Canada	30 positive	Cutoff ≤ 37			76.9%, Ct < 25		

632 **Table 3. Comparisons with other RT-LAMP PoC SARS-CoV-2 tests**

29 negative				0%, Ct > 30		
NP samples	20 - 36	100%	84%	100%, Ct < 32	None	562C, 1 hour
19 positive						
21 negative						
NP samples	14.3 - 38.2	89.3%	73%	97.3%, Ct < 30	None	982C, 15 min
74 positive						
28 negative						
Saliva samples	18 - 28	100%	85%	100%, Ct < 22.2	None	952C, 30 min
39 positive						
15 negative						
NP samples	0-40	99.5%	46.9%	90.5%, Ct < 25	None	95°C, 5 min
128 positive				17.9%, Ct: 30 - 35		
215 negative						
NP samples	8 - 34	100%	83.3%	100%, Ct ≤ 25	None	Pretreated with
96 positive				53.1%, Ct: 30 - 34		neutralizing buffer
67 negative						
	29 negative NP samples 19 positive 21 negative 21 negative 28 negative 28 negative 28 negative 39 positive 15 negative 15 negative 215 negative 215 negative 215 negative 67 negative	29 negativeNP samples20 - 3619 positive2121 negative14.3 - 38.2NP samples14.3 - 38.274 positive2828 negative18 - 2839 positive18 - 2839 positive19 - 2815 negative10 - 40128 positive0 - 40128 positive8 - 3496 positive8 - 3496 positive67 negative	29 negative20 - 36100%NP samples20 - 36100%19 positive21 negative2121 negative14.3 - 38.289.3%74 positive28 negative2828 negative18 - 28100%39 positive18 - 28100%15 negative215 negative99.5%128 positive215 negative100%96 positive8 - 34100%67 negative1100%1100%	29 negative20 - 36100%84%19 positive100%84%19 positive100%84%21 negative100%85%NP samples14.3 - 38.289.3%73%74 positive28 negative100%85%28 negative18 - 28100%85%39 positive18 - 28100%85%39 positive18 - 28100%85%15 negative0 - 4099.5%46.9%128 positive100%83.3%96 positiveNP samples8 - 34100%83.3%96 positive67 negative100%83.3%	29 negative 0%, Ct > 30 NP samples 20 - 36 100% 84% 100%, Ct < 32	29 negative 20 - 36 100% 84% 100%, Ct < 30

633

*, positive samples had been treated for viral inactivation before, not for the purpose of assay optimization

634

635 We compared our direct detection results to those of five other RT-LAMP studies (Table 636 3). Dao Thi et al [21], based in Heidelberg Germany, used N-A gene primers in RT-LAMP, and 637 observed sensitivity of ~47% at 99.5% specificity, which is in a similar range to each of our 638 three cohorts (Table 3). Similar to our work, Schermer et al, based in Cologne Germany, 639 developed a multiplex reaction that included guanidine [19]. They reported a sensitivity of 73% 640 with randomly selected samples, above our best result of 53.3%, but specificity was only 89% in 641 contrast to 100% in our study (Table 3). It would be interesting to run comparisons on the same samples with primer sets used in both studies. Song et al, using samples from Pennsylvania 642 USA, used a two-step tube reaction ("Penn-RAMP") in which recombinase polymerase 643

644 amplification (RT-RPA) was performed first in the lid, then after spin-down, RT-LAMP in the 645 tube [18]. They reported 84% sensitivity at 100% specificity, and detected all samples with Ct <646 32. Thus, adding the RT-RPA step greatly enhances sensitivity. A drawback is that this strategy 647 requires additional reagents and a centrifuge, which can pose a challenge for operation in lowresource settings. For example, as we experienced, there are no direct suppliers of RPA or 648 649 LAMP reagents in Colombia or Ecuador, and orders can take 2-6 months to arrive. Moreover, we 650 found the performance of some products was lower than what was experienced in Canada, likely 651 due to disruption of the cold chain during transport or customs clearance. Nation-specific 652 bureaucratic requirements can further delay reagent delivery; for example, the National Institute 653 for Food and Drug Surveillance (INVIMA) in Colombia must approve all reagents, which can affect preservation of reagents requiring cold chain. All of these challenges have been 654 655 exasperated in the pandemic with, for example, customs personnel working from home and slower administrative approval processes. 656

It is worth noting that Song et al also tested Penn-RAMP with virion RNA in a PoC 657 658 heating block [18], but whether this approach works with raw samples to the extent seen in the 659 dual-step tube format was not reported. Nevertheless, their data highlight the potential of using RPA to improve RT-LAMP. A study by Papadakis et al from Heraklion Greece developed a 660 portable biomedical device for performing real-time quantitative colorimetric LAMP. They 661 performed RT-LAMP with Bst DNA/RNA polymerase from SBS Genetech, and tested 67 662 663 negative and 96 positive crude NP samples [22]. They reported 100% sensitivity at Ct \leq 25 and 53.1% sensitivity at Ct: 30 – 34 with 100% specificity. Compared with our results, their reported 664 665 higher sensitivity at high Ct values is likely due to the polymerase used, which is extremely thermostable and also provides sensitive reverse transcriptase activity. In their study, samples 666

were pretreated with neutralization buffer. Finally, Amaral *et al* [20], based in Lisbon Portugal, assessed saliva rather than NP samples, which has the advantage of easier collection. They observed 85% sensitivity at 100% specificity, but the highest RT-PCR Ct value of their samples was only 28; indeed 100% sensitivity was only observed at Ct < 22.2 (Table 3). Overall, RT-LAMP alone seems best suited to detect high titer samples.

672 In the final phase of our diagnostic development program, we prototyped deployment of the assay with a portable "lab-in-a-box" that provided combined incubation, optical monitoring 673 and graphing. Direct RT-LAMP with the FluorPLUM device displayed high sensitivity with high 674 675 viral loads (76.9% for Ct < 25 and 100% for Ct < 22.5), which dropped dramatically with low viral loads (Ct > 25). Thus, most samples with viral load beyond 7.9 X 10^6 copies/mL could be 676 677 detected. These data were comparable to results obtained with thermocyclers, justifying future work to assess this strategy in the field. Work is on-going to provide a more robust platform for 678 679 field testing to broaden accessibility of FluoroPLUM as a PoC device.

680 Through the lens of maintaining public health, the priority is not necessarily to determine whether a person has any evidence of SARS-CoV-2, but to quickly and accurately identify 681 682 individuals who are infectious [14]. Various studies have shown that COVID-19 patient sample 683 infectivity correlates with Ct values, and the infectious period corresponds to the period during which viral load is likely to be highest [10–12,53,54]. Furthermore, a recent study directly 684 demonstrated that viral load of COVID-19 patients was a leading driver of SARS-CoV-2 685 686 transmission [55]. In that study, 282 COVID-19 cases were tracked and only 32% led to 687 transmission [55]. Among the 753 total contacts from these cases, the secondary attack rate overall was 17%. Critically, at the lower viral load (10^6 copies per mL) the secondary attack rate 688 was 12% compared to 24% when the case had a viral load of 10^{10} copies per mL or higher [55]. 689

690 In comparison with our RT-LAMP assay, the detection sensitivity for samples with Ct < 25(viral load > 7.9 X 10^6 copies per mL) was 76.9%, and 100% for samples with Ct ≤ 22.5 (viral 691 load $\ge 5 \times 10^7$ copies per mL), suggesting most individuals with high risk for transmission 692 would be identified. The turnaround time for laboratory-based RT-PCR testing is generally 24 to 693 694 48 hours, and longer in remote areas due to the transport of samples, while the RT-LAMP assay would generate results on-site in less than one hour. Thus, our assay could potentially be 695 696 deployed as a PoC test at distributed sample collection centers to identify individuals with high 697 risk for transmission to mitigate virus spreading.

698 A limitation of our study is that we tested NP swab samples processed in research laboratories, not in the field. Nevertheless, the lab studies in Colombia and Ecuador indicate 699 700 feasibility and set the stage for PoC tests. A limitation of all LAMP protocols is that both the 701 supply and cold chains remain a major hurdle for low/mid income nations. Many countries lack 702 the domestic capacity for diagnostic manufacturing and must import health care tools, which, in 703 addition to possible delays and cost, can complicate the response to public health crises. Cellfree protein expression systems, produced from E. coli, offer an exciting solution, and indeed 704 705 have been applied recently in Chile for detection of a plant pathogen [56]. This trend toward 706 locally produced reagents promises to transform diagnostics and reduce costs by orders of 707 magnitude. As a part of the ongoing collaboration among the laboratories included in this study, 708 a research project to locally produce easy-to-implement low-cost kits for the molecular diagnosis 709 of febrile diseases (Sars-Cov-2 and arbovirus), was recently funded by the Ministry of Sciences 710 (Minciencias) in Colombia.

In summary, we developed a rapid RT-LAMP assay for SARS-CoV-2 detection which
was essentially as accurate as the BGI RT-PCR kit with extracted RNA, suggesting that it can

- substitute for laboratory RT-PCR testing. With raw NP samples, the direct RT-LAMP assay
- detected samples with high viral loads, positioning the assay well for future deployment as a PoC
- 715 test to control virus spread.
- 716

717 **References**

- Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19.
 JAMA. 2020;324: 2153–2154. doi:10.1001/jama.2020.21694
- Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2
 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19: 409–424.
 doi:10.1038/s41579-021-00573-0
- Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available from
 www.who.int/news/item/26-11-2021-classification-of-omicron.
- Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity A Strategy for
 Containment. N Engl J Med. 2020;383: e120. doi:10.1056/NEJMp2025631
- 7275.He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and728transmissibility of COVID-19. Nat Med. 2020;26: 672–675. doi:10.1038/s41591-020-0869-5
- Townsend JP, Wells CR. The Prognostic Value of an RT-PCR Test for Severe Acute Respiratory
 Syndrome Coronavirus 2 (SARS-CoV-2) Is Contingent on Timing across Disease Time Course in
 addition to Assay Sensitivity. J Mol Diagn. 2022;24: 101–103. doi:10.1016/j.jmoldx.2021.10.002
- 7. Tian D, Lin Z, Kriner EM, Esneault DJ, Tran J, DeVoto JC, et al. Ct Values Do Not Predict Severe
 733 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmissibility in College Students. J Mol
 734 Diagn JMD. 2021;23: 1078–1084. doi:10.1016/j.jmoldx.2021.05.012
- 8. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to
 frequency and turnaround time for COVID-19 surveillance. MedRxiv Prepr Serv Health Sci. 2020.
 doi:10.1101/2020.06.22.20136309
- 9. Service RF. A call for diagnostic tests to report viral load. Science. 2020;370: 22.
 doi:10.1126/science.370.6512.22
- 10. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as
 determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from
 infectious disease wards. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020;39:
 1059–1061. doi:10.1007/s10096-020-03913-9

- Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious SARS-CoV-2
 from diagnostic samples. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. doi:10.1093/cid/ciaa638
- Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, et al. Cell-based culture of SARS CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. Clin Infect Dis Off
 Publ Infect Dis Soc Am. 2020. doi:10.1093/cid/ciaa1579
- 13. Chin ET, Lo NC, Huynh BQ, Murrill M, Basu S. Frequency of routine testing for SARS-CoV-2 to
 reduce transmission among workers. MedRxiv Prepr Serv Health Sci. 2020.
 doi:10.1101/2020.04.30.20087015
- Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19.
 JAMA. 2020. doi:10.1001/jama.2020.21694
- Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-care antigen
 and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Infectious Diseases
 Group, editor. Cochrane Database Syst Rev. 2021;2021. doi:10.1002/14651858.CD013705.pub2
- Augustine R, Hasan A, Das S, Ahmed R, Mori Y, Notomi T, et al. Loop-Mediated Isothermal
 Amplification (LAMP): A Rapid, Sensitive, Specific, and Cost-Effective Point-of-Care Test for
 Coronaviruses in the Context of COVID-19 Pandemic. Biology. 2020;9. doi:10.3390/biology9080182
- MacKay MJ, Hooker AC, Afshinnekoo E, Salit M, Kelly J, Feldstein JV, et al. The COVID-19 XPRIZE
 and the need for scalable, fast, and widespread testing. Nat Biotechnol. 2020;38: 1021–1024.
 doi:10.1038/s41587-020-0655-4
- Song J, El-Tholoth M, Li Y, Graham-Wooten J, Liang Y, Li J, et al. Single- and Two-Stage, Closed Tube, Point-of-Care, Molecular Detection of SARS-CoV-2. Anal Chem. 2021;93: 13063–13071.
 doi:10.1021/acs.analchem.1c03016
- Schermer B, Fabretti F, Damagnez M, Di Cristanziano V, Heger E, Arjune S, et al. Rapid SARS-CoV-2
 testing in primary material based on a novel multiplex RT-LAMP assay. PloS One. 2020;15:
 e0238612. doi:10.1371/journal.pone.0238612
- Amaral C, Antunes W, Moe E, Duarte AG, Lima LMP, Santos C, et al. A molecular test based on RTLAMP for rapid, sensitive and inexpensive colorimetric detection of SARS-CoV-2 in clinical samples.
 Sci Rep. 2021;11: 16430. doi:10.1038/s41598-021-95799-6
- Dao Thi VL, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, et al. A colorimetric RT-LAMP
 assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. Sci Transl Med.
 2020;12: eabc7075. doi:10.1126/scitranslmed.abc7075
- Papadakis G, Pantazis AK, Ntogka M, Parasyris K, Theodosi G-I, Kaprou G, et al. 3D-printed Point-of Care Platform for Genetic Testing of Infectious Diseases Directly in Human Samples Using Acoustic
 Sensors and a Smartphone. ACS Sens. 2019;4: 1329–1336. doi:10.1021/acssensors.9b00264
- Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)
 Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food

- and Drug Administration Staff. Document issued on the web on May 11, 2020. Available from
 https://www.fda.gov/media/135659/download.
- Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, et al. Rapid Molecular Detection of SARS CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. Infectious Diseases (except HIV/AIDS); 2020
 Feb. doi:10.1101/2020.02.26.20028373
- Rabe BA, Cepko C. SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive
 protocol for sample inactivation and purification. Proc Natl Acad Sci U S A. 2020;117: 24450–
 24458. doi:10.1073/pnas.2011221117
- 26. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel coronavirus/Severe Acute
 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated
 isothermal amplification. PloS One. 2020;15: e0234682. doi:10.1371/journal.pone.0234682
- Zhang Y, Ren G, Buss J, Barry AJ, Patton GC, Tanner NA. Enhancing colorimetric loop-mediated
 isothermal amplification speed and sensitivity with guanidine chloride. BioTechniques. 2020;69:
 178–185. doi:10.2144/btn-2020-0078
- Broughton JP, Deng X, Yu G, Fasching CL, Singh J, Streithorst J, et al. Rapid Detection of 2019 Novel
 Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay. MedRxiv Prepr Serv
 Health Sci. 2020. doi:10.1101/2020.03.06.20032334
- Diagnostic detection of 2019-nCoV by real-time RT-PCR. -Protocol and preliminary evaluation as of
 Jan 17, 2020- Victor Corman et al., Available from www.who.int/docs/default source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2.
- 80030.Detection of 2019 novel coronavirus (2019-nCoV) in suspected human cases by RT-PCR. Available801from www.who.int/docs/default-https://www.who.int/docs/default-source/coronaviruse/peiris-802protocol-16-1-20.pdf?sfvrsn=af1aac73_4.
- B03 31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
 receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44: 837–845.
- S2. Chou P-H, Lin Y-C, Teng P-H, Chen C-L, Lee P-Y. Real-time target-specific detection of loop mediated isothermal amplification for white spot syndrome virus using fluorescence energy
 transfer-based probes. J Virol Methods. 2011;173: 67–74. doi:10.1016/j.jviromet.2011.01.009
- Ahn SJ, Baek YH, Lloren KKS, Choi W-S, Jeong JH, Antigua KJC, et al. Rapid and simple colorimetric
 detection of multiple influenza viruses infecting humans using a reverse transcriptional loopmediated isothermal amplification (RT-LAMP) diagnostic platform. BMC Infect Dis. 2019;19: 676.
 doi:10.1186/s12879-019-4277-8
- 34. Torres C, Vitalis EA, Baker BR, Gardner SN, Torres MW, Dzenitis JM. LAVA: an open-source
 approach to designing LAMP (loop-mediated isothermal amplification) DNA signatures. BMC
 Bioinformatics. 2011;12: 240. doi:10.1186/1471-2105-12-240
- 81535.Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human816respiratory disease in China. Nature. 2020;579: 265–269. doi:10.1038/s41586-020-2008-3

- 81736.Burd EM. Validation of laboratory-developed molecular assays for infectious diseases. Clin818Microbiol Rev. 2010;23: 550–576. doi:10.1128/CMR.00074-09
- Foo PC, Chan YY, Mohamed M, Wong WK, Nurul Najian AB, Lim BH. Development of a
 thermostabilised triplex LAMP assay with dry-reagent four target lateral flow dipstick for detection
 of Entamoeba histolytica and non-pathogenic Entamoeba spp. Anal Chim Acta. 2017;966: 71–80.
 doi:10.1016/j.aca.2017.02.019
- 38. Mahony J, Chong S, Bulir D, Ruyter A, Mwawasi K, Waltho D. Multiplex loop-mediated isothermal
 amplification (M-LAMP) assay for the detection of influenza A/H1, A/H3 and influenza B can
 provide a specimen-to-result diagnosis in 40 min with single genome copy sensitivity. J Clin Virol
 Off Publ Pan Am Soc Clin Virol. 2013;58: 127–131. doi:10.1016/j.jcv.2013.06.006
- 39. Dudley DM, Newman CM, Weiler AM, Ramuta MD, Shortreed CG, Heffron AS, et al. Optimizing
 direct RT-LAMP to detect transmissible SARS-CoV-2 from primary nasopharyngeal swab samples.
 Kalendar R, editor. PLOS ONE. 2020;15: e0244882. doi:10.1371/journal.pone.0244882
- 83040.Henke W, Herdel K, Jung K, Schnorr D, Loening SA. Betaine improves the PCR amplification of GC-831rich DNA sequences. Nucleic Acids Res. 1997;25: 3957–3958. doi:10.1093/nar/25.19.3957
- 41. Yao Y, Li Y, Liu Q, Zhou K, Zhao W, Liu S, et al. Rapid detection of hepatocellular carcinoma
 metastasis using reverse transcription loop-mediated isothermal amplification. Talanta. 2020;208:
 120402. doi:10.1016/j.talanta.2019.120402
- He X, Xue F, Xu S, Wang W. Rapid and sensitive detection of Lily symptomless virus by reverse
 transcription loop-mediated isothermal amplification. J Virol Methods. 2016;238: 38–41.
 doi:10.1016/j.jviromet.2016.10.003
- 43. Garg A, Ghoshal U, Patel SS, Singh DV, Arya AK, Vasanth S, et al. Evaluation of seven commercial
 RT-PCR kits for COVID-19 testing in pooled clinical specimens. J Med Virol. 2021;93: 2281–2286.
 doi:10.1002/jmv.26691
- 44. Pearson JD, Trcka D, Lu S, Hyduk SJ, Jen M, Aynaud M-M, et al. Comparison of SARS-CoV-2 indirect
 and direct RT-qPCR detection methods. Virol J. 2021;18: 99. doi:10.1186/s12985-021-01574-4
- 45. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac
 Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5: 1315–1316.
 doi:10.1097/JTO.0b013e3181ec173d
- 846 46. Shatzkes K, Teferedegne B, Murata H. A simple, inexpensive method for preparing cell lysates
 847 suitable for downstream reverse transcription quantitative PCR. Sci Rep. 2014;4: 4659.
 848 doi:10.1038/srep04659
- 47. Arnaout R, Lee RA, Lee GR, Callahan C, Yen CF, Smith KP, et al. SARS-CoV2 Testing: The Limit of
 Detection Matters. BioRxiv Prepr Serv Biol. 2020. doi:10.1101/2020.06.02.131144
- 48. Health C for D and R. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. FDA. 2021 [cited 10
 Jan 2022]. Available: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medicaldevices/sars-cov-2-viral-mutations-impact-covid-19-tests

854 855 856	49.	MacKay MJ, Hooker AC, Afshinnekoo E, Salit M, Kelly J, Feldstein JV, et al. The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing. Nat Biotechnol. 2020;38: 1021–1024. doi:10.1038/s41587-020-0655-4
857 858 859 860	50.	World Health Organization. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0. Available from https://www.who.int/publications/m/item/ covid-19-target-product-profiles-for-priority-diagnostics-tosupport- response-to-the-covid-19-pandemic-v.0.1 2020.
861 862	51.	Manabe YC, Sharfstein JS, Armstrong K. The Need for More and Better Testing for COVID-19. JAMA. 2020. doi:10.1001/jama.2020.21694
863 864	52.	Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med. 2020;383: e120. doi:10.1056/NEJMp2025631
865 866 867	53.	Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581: 465–469. doi:10.1038/s41586-020-2196-x
868 869	54.	Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2020;26: 842–847. doi:10.1016/j.cmi.2020.04.023
870 871 872	55.	Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monné M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21: 629–636. doi:10.1016/S1473-3099(20)30985-3

Arce A, Guzman Chavez F, Gandini C, Puig J, Matute T, Haseloff J, et al. Decentralizing Cell-Free
RNA Sensing With the Use of Low-Cost Cell Extracts. Front Bioeng Biotechnol. 2021;9: 727584.
doi:10.3389/fbioe.2021.727584

876

877 Supporting information

878 S1 Fig. Primer set performance at a low copy number of SARS-CoV-2 RNA (related to Fig

- **1).** Primer sets for: (A) GeneN-A and GeneN-A^{4T}; (B) N-gene and N-gene^{4T}; (C) ORF1a-C and
- 880 ORF1a-C^{4T}; (D) Gene E1^{4T} and ORF1a^{4T}; (E) Gene N2 and Gene N2^{4T}; (F) As1e and ACTB^{4T}.
- NTC, no template control; PC, positive control (30 copies of SARS-CoV-2 RNA); TTR, time to
- results (min); Error bars represent mean \pm standard deviations.

S2 Fig. Fluorescence plots and end-point color changes for LoD and specificity assays
(related to Fig 2). Fluorescent readouts and images of color changes at 60 minutes are shown for
the following primer sets: (A) Gene E1. (B) N-gene. (C) Gene N2. (D) ORF1a. (E) ACTB.
Primer amounts (F3B3/FIPBIP/LFBF, μM) are indicated above each assay. Each condition was
evaluated with 10 replicates. RFU, relative fluorescence units; NTC, no template control.

S3 Fig. Effect of primer set multiplexing and guanidine hydrochloride and betaine 888 supplements (related to Fig 3). (A) Fluorescent readouts of RT-LAMP with the indicated 889 primer multiplexing (also see Fig3A). (B) Phenol red colour at 60 minutes from assays in (A). 890 891 (C) Fluorescent readouts of RT-LAMP with multiplexed primer sets for Gene E1 and ORF1a with the indicated supplements (also see Fig3B). (D) Phenol red colour at 60 minutes from 892 assays in (C). RT-LAMP reactions were performed with 15 copies of SARS-Cov-2 RNA, and 893 each condition was evaluated with 10 replicates. NTC, no template control; RFU, relative 894 895 fluorescence units.

896 **S4 Fig. End-point color changes for RT-LAMP reactions with extracted clinical RNA** 897 **compared to Ct values for RT-PCR (related to Fig 4)**. (A) Phenol red colour of RT-LAMP 898 assays with extracted RNA from clinical NP samples. RT-LAMP was carried out in a water 899 batch at 65°C for 25 minutes with multiplexed Gene E1 and ORF1a primers and 40mM and 900 0.5M betaine. (B) Sensitivity and specificity in (A). NTC, no template control; PC, positive 901 control (240 copies of SARS-CoV-2 and 1ng human RNA).

902 S5 Fig. ACTB detection using the direct RT-LAMP method without RNA extraction 903 (related to Fig 5). (A) Distribution of ACTB TTRs of raw clinical NP samples under the

- 904 indicated RT-LAMP conditions. (B) Distribution of ACTB TTRs between RT-LAMP test
- 905 positive and negative from contrived raw positive NP samples.

906 S6 Fig. Optimization of SYTO 9 concentration for direct RT-LAMP with FluoroPLUM

- 907 (related to Fig 7). RT-LAMP for ACTB was performed with 10 clinical NP samples with the
- indicated SYTO 9 concentrations. Bars represented the mean slope₂₀₋₄₀. A paired t-test was used
- to assess differences in the means. *, P < 0.05; **, P < 0.01.

Fig 1



Α			SAF	RS-Co	/2 prin	ners				
	Primers	F3B3/FIPBIP/LFLB (µM)	(Copies)	So 30	ensitivi 60	ty 120	240	LoD	Speci (Min) 45	ficity 60
	ORF1a	0.2/3.2/0.4		4/10	9/10	10/10	10/10	120	10/10	0 6/10
		0.2/1.6/0.4		3/10	5/10	8/10	10/10	240	9/10	6/10
	Gene E1	0.2/3.2/0.4		4/10	9/10	9/10	10/10	240	10/10	10/10
		0.2/1.6/0.8		3/10	6/10	9/10	10/10	240	10/10	7/10
	Gene N2	0.2/3.2/0.4		2/10	4/10	8/10	10/10	240	10/10	10/10
		0.2/1.6/0.8		6/10	6/10	9/10	10/10	240	9/10	7/10
	N-gene	0.4/3.2/0.8		4/10	7/10	9/10	10/10	240	10/10	8/10
		0.4/6.4/0.8		2/10	6/10	9/10	10/10	240	7/10) 1/10

В

ACTB primers													
Primer	F3B3/FIPBIP/LFLB		Sensiti	vity	LoD	Specificity							
	(μM)	(ng) 0.0	1 0.05	0.25	1.25		(Min) 45 60						
АСТВ	0.05/0.4/0.1	10/:	10/10	10/10	10/10	<0.01	10/10 10/10						
	0.05/0.8/0.2	10/2	.0 10/10	10/10	10/10	<0.01	8/10 8/10						

С



LoD assessment of optimized RT-LAMP

Primers	Supplements		LoD			
		(Copies) 7.5	15	20	25	
Gene E1 + ORF1a	40 mM GuHCl + 0.5 M Betaine	4/10	9/10	10/10	10/10	20





Fig 5





Fig 7







S2 Fig



S3 Fig



A Samples	N1	N2	N3	N4	N5	N6	N7	N8	N9	N10	P1	P2	P3	P4	P7	Р9	P10	NTC	NTC	РС	
Ct ^{ORF1ab}	N/A	N/A	29.1	25.3	30.3	29.1	24.8	36.2	32.9	N/A	N/A	N/A									
Ct ^{ACTB}	28.6	30.7	28.6	27.5	26.3	29.7	30.5	28.8	31.6	30.6	27.1	26.0	31.9	26.3	26.2	27.1	32.1	N/A	N/A	N/A	
	2	3	3	1	5	6	2	8	2	10	8	8	8	8	8	8	0	9	9	0	SARS-CoV2
	8	8		A	8		3	*	0		0		3	3		3	3	•	9	0	АСТВ
Samples	N11	N12	N13	N14	N15	P11	P12	P13	P14	P15	N16	N17	N18	N19	N20	N21	P16	P18	P19	P20	
CtORFiab	N/A	N/A	N/A	N/A	N/A	24.8	32.5	32.8	19.0	27.1	N/A	N/A	N/A	N/A	N/A	N/A	36.9	18.0	33.1	20.5	
Ct ^{ACTB}	27.1	32.5	27.2	25.9	26.7	26.6	26.6	27.1	28.2	27.3	26.3	26.3	28.9	29.3	26.2	27.1	28.4	29.2	31.3	27.1	
	2	20	30	2	5	6	3	8	2	10	A	3	A	A	A	6	A	-	20	10	SARS-CoV2
	0	0	0		0	0	0	0	0	0	A	-	A	-	9	A		9	2	2	АСТВ
Samples	N22	N23	N24	N25	N26	N27	N28	N29	N30	P21	P23	P24	P25	P26	P27	P28	P29	P30	P31		
Ct ^{ORF1ab}	N/A	31.6	22.4	24.6	20.1	. 21.2	30.0	24.8	24.7	30.2	28.5										
Ctacib	28.2	26.2	27.1	25.9	30.2	27.4	28.1	27.5	26.2	26.5	26.1	27.8	26.7	25.7	31.7	27.4	28.4	29.2	29.3		
	2	2	A	A	A	0	0	Å	0		0	9	9	9		50	8	0	0	SARS	S-CoV2
	0		8		0			9	0	9	9	9	0	0	0		0	0	0	ACTE	3
Samples	N31	N32	N33	N34	N35	N36	P32	P34	P35 F	236 N	rc n'	TC P	С								
Ct ^{ORF1ab}	N/A	N/A	N/A	N/A	N/A	N/A	36.2	21.2	22.6 2	22.4 N	/A N	/A N	/A								
Ct ^{ACTB}	28.2	26.2	27.1	25.9	30.2	27.4	26.2	27.1	28.1 2	26.2 N	A N	/A N	/A		п						
	19	2	3	*	5	6	*	6	A	No la	9	0	s.	ARS-Co	В V2	Se	nsitiv	ity = 2	8/30	= 93.	3%
	0		8	0		0	-	9	9	8	0	•	A	СТВ		Sp	ecific	ity = 3	6/36	= 100)%





